194 results on '"Rovira, Ana"'
Search Results
2. The impact of mutational clonality in predicting the response to immune checkpoint inhibitors in advanced urothelial cancer
3. miR-146a-5p Promotes Angiogenesis and Confers Trastuzumab Resistance in HER2+ Breast Cancer
4. The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors
5. Role of SALL4 in HER2+ Breast Cancer Progression: Regulating PI3K/AKT Pathway
6. Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations
7. Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer
8. Enhanced MAF Oncogene Expression and Breast Cancer Bone Metastasis
9. mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer
10. CIP2A as a Key Regulator for AKT Phosphorylation Has Partial Impact Determining Clinical Outcome in Breast Cancer
11. Shift towards autogamy in the extremely narrow endemic Aquilegia paui and comparison with its widespread close relative A. vulgaris (Ranunculaceae)
12. Nocturnal pollination of the endemic Silene sennenii (Caryophyllaceae): an endangered mutualism?
13. Targeted Therapy Modulates the Secretome of Cancer-Associated Fibroblasts to Induce Resistance in HER2-Positive Breast Cancer
14. Typification of Some Macaronesian and Mediterranean Dendroid Spurges
15. Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer
16. The Novel Oral mTORC1/2 Inhibitor TAK-228 Reverses Trastuzumab Resistance in HER2-Positive Breast Cancer Models
17. El Lloret d'abans. D'estiuejants a turistes: Projecte de muselologia per al Castell d'en Plaja de Lloret de Mar
18. Increased ALK Gene Copy Number and Amplification are Frequent in Non-small Cell Lung Cancer
19. MicroRNA-33b Suppresses Epithelial–Mesenchymal Transition Repressing the MYC–EZH2 Pathway in HER2+ Breast Carcinoma
20. Autocrine CCL5 Effect Mediates Trastuzumab Resistance by ERK Pathway Activation in HER2-Positive Breast Cancer
21. The Hippo Pathway Transducers YAP1/TEAD Induce Acquired Resistance to Trastuzumab in HER2-Positive Breast Cancer
22. Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation
23. HER-Family Ligands Promote Acquired Resistance to Trastuzumab in Gastric Cancer
24. Demographic Monitoring and Verification of Chromosomal Variability of the Bolòs Larkspur (Delphinium Bolosii) in the Sant Llorenç del Munt i l’Obac Nature Park
25. Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer
26. Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models
27. Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer
28. NK Cell Infiltrates and HLA Class I Expression in Primary HER2+ Breast Cancer Predict and Uncouple Pathological Response and Disease-free Survival
29. Extranodal Natural Killer/T-Cell Lymphoma Nasal Type in 87 Cases from Spain: Clinical Presentation, Treatment and Prognostic Factors. Study from the Geltamo Group
30. Análisis de la influencia de las características evolutivas del concreto en los tiempos de construcción de sótanos
31. Generation, characterization, and maintenance of trastuzumab-resistant HER2+ breast cancer cell lines
32. Stable in vivo expression of glucose-6-phosphate dehydrogenase (G6PD) and rescue of G6PD deficiency in stem cells by gene transfer
33. Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer
34. Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy
35. The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 gene
36. c-Jun N-Terminal Kinase Inactivation by Mitogen-Activated Protein Kinase Phosphatase 1 Determines Resistance to Taxanes and Anthracyclines in Breast Cancer
37. Estudi preliminar de variabilitat isoenzimàtica de Delphinium bolosii al Parc Natural de Sant Llorenç del Munt i l’Obac
38. Abstract 2149: The anti-EGFR antibody mixture Sym004 overcomes acquired resistance to cetuximab in colorectal cancer
39. Non-canonical NF-κB pathway activation predicts outcome in borderline oestrogen receptor positive breast carcinoma
40. The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer
41. FoxA and LIPG endothelial lipase control the uptake of extracellular lipids for breast cancer growth
42. Estructura i diversitat genètica de les poblacions pirinenques de Dichoropetalum schottii (Bess.) Pimenov & Kljuykov (Apiaceae): avaluació per a l’establiment de prioritats en conservació
43. Geltamo-IPI Distinctly Identifies a Very High Risk Group in Difuse Large B-Cell Lymphoma (DLBCL) of Non B-Germinal-Center Origin Treated with Chemo-Immunotherapy
44. Enhancing tumor-targeting monoclonal antibodies therapy by PARP inhibitors
45. Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer
46. PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects
47. Snail1-Expressing Fibroblasts in the Tumor Microenvironment Display Mechanical Properties That Support Metastasis
48. Methylation status ofIGFBP-3as a useful clinical tool for deciding on a concomitant radiotherapy
49. High circulating hepatocyte growth factor levels associate with epithelial to mesenchymal transition and poor outcome in small cell lung cancer patients
50. Targeting Epithelial-to-Mesenchymal Transition with Met Inhibitors Reverts Chemoresistance in Small Cell Lung Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.